第28届京台科技论坛——京台生物科技合作发展论坛在北京亦庄举办

Core Insights - The 28th Beijing-Taipei Technology Forum focused on "Innovation-Driven Integrated Development: Jointly Building a New Ecosystem for the Biotechnology Industry" and gathered representatives from both regions to discuss trends and collaboration opportunities in the biopharmaceutical sector [1][2] Group 1: Policy and Regulatory Framework - The Deputy Director of Beijing's Drug Administration highlighted the "Measures to Support the High-Quality Development of Innovative Pharmaceuticals in Beijing (2025)", emphasizing policies related to clinical trials, approval processes, production, circulation, clinical application, and investment support [1] - The administration aims to enhance innovation services, expedite review processes, and improve inspection efficiency to promote high-quality development in the pharmaceutical and health industry [1] Group 2: Industry Trends and Innovations - Discussions included topics such as natural drug development, ADC innovation technology, cell and gene therapy, AI-assisted pathology diagnosis, and exosome technology [1] - Companies like Tianjin Biotechnology Group and Yuyuan Pharmaceutical shared insights on their innovative products, including the first approved natural new drug for diabetic foot ulcers and advancements in ADC technology [1][2] - The Chinese innovative pharmaceutical industry is transitioning from a "follower" to a key global innovator, with ongoing improvements needed in original innovation capabilities and global competitiveness [1] Group 3: Industry Growth and Economic Impact - The Beijing Economic and Technological Development Zone hosts over 5,000 companies in the biotechnology and health sector, with projected industrial output value of 81.3 billion yuan in 2024 and a 16.6% year-on-year revenue growth in the technology service sector [2] - The establishment of the International Pharmaceutical Innovation Park (BioPark) has attracted major international companies like AstraZeneca, Eli Lilly, Pfizer, and Bayer, with all six centers of the National Medical Products Administration now located there [2]